First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743

A. Scherpereel, S. Antonia, Y. Bautista, F. Grossi, D. Kowalski, G. Zalcman, A. Nowak, N. Fujimoto, S. Peters, A. Tsao, A. Mansfield, S. Popat, X. Sun, B. Padilla, P. Aanur, M. Daumont, B. Bennett, M. McKenna, P. Baas

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

5 Citations (Web of Science)
Original languageEnglish
Pages (from-to)S1441-S1441
Number of pages1
JournalAnnals of Oncology
Publication statusPublished - Dec 2020
EventESMO Immuno-Oncology Virtual Congress -
Duration: 9 Dec 202012 Dec 2020

Cite this